Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) has reported a sharp increase in net profit for the fourth quarter of 2022 when its revenues moved up 2%. Revenues increased by 2% annually to $7.4 billion in the final three months of fiscal 2022. A 58% increase in international product sales more than offset weakness in […]
“Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) has reported a sharp increase in net profit for the fourth quarter of 2022 when its revenues moved up 2%. Revenues increased by 2% annually to $7.4 billion in the final three months of fiscal 2022. A 58% increase in international product sales more than offset weakness in […]
· February 3, 2023
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) has reported a sharp increase in net profit for the fourth quarter of 2022 when its revenues moved up 2%.
Revenues increased by 2% annually to $7.4 billion in the final three months of fiscal 2022. A 58% increase in international product sales more than offset weakness in the European market. Meanwhile, US sales remained broadly unchanged.
Net income, on a reported basis, more than doubled year-over-year to $1.6 billion or $1.30 per share during the three-month period. Adjusted earnings climbed to $1.67 per share.
